Preliminary Communications

Azathioprine in Rheumatoid Arthritis

Br Med J 1969; 1 doi: (Published 15 February 1969) Cite this as: Br Med J 1969;1:420
  1. Michael Mason,
  2. H. L. F. Currey,
  3. Colin G. Barnes,
  4. J. F. Dunne,
  5. B. L. Hazleman,
  6. I. D. Strickland


    The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo. After 12 months a significant mean dose reduction of 36% was achieved without undue side-effects. This form of therapy promises to be an advance in the management of severe rheumatoid arthritis.

    Log in

    Log in through your institution


    * For online subscription